The Complex History of Phencyclidine (PCP) Explained

Empty glass bottle with water and a cork stopper in a natural outdoor setting, symbolizing detox and recovery.

Key Takeaways

  • PCP was originally developed in the mid-20th century as a promising surgical anesthetic, but its use was abandoned by 1965 due to severe side effects like agitation and psychosis.
  • After being repurposed for veterinary medicine, the drug transitioned into an illicit substance, leading to strict government regulation and its eventual reclassification as a Schedule II controlled substance in 1978.
  • While recreational use declined significantly after the 1970s, PCP remains a valuable tool in modern neurobiology for studying the NMDA receptor and the biological mechanisms of schizophrenia.

Phencyclidine, known as PCP, has a long history from its start as a medical anesthetic to its shift into a dangerous, illicit substance in the modern era.

The Scientific Beginnings: 1926 to 1956

The story of PCP began in 1926. Chemists Arthur Kötz and Paul Merkel successfully created the compound using a reaction called a Grignard reaction. To be fair, this was a massive scientific breakthrough, but the substance sat on the shelf for years. Nobody really knew what to do with it.

It wasn’t until 1956 that H. Victor Maddox, working for the drug company Parke-Davis, took a closer look. He saw potential in it as a tool for surgery. They eventually patented it under the name Sernyl. At the time, they really believed it would change how doctors performed operations.

Medical Application and Rapid Decline: 1957–1965

By 1957, Sernyl moved into clinical trials. Doctors liked that it could block pain—which is called analgesia—without slowing down a patient’s breathing or heart rate. That seemed like a win.

But wait—things turned south quickly. Doctors noticed that patients were waking up from surgery in a state of wild confusion. They felt anxious, agitated, and experienced what looked like psychosis. These “emergent reactions” were, frankly, terrifying. Because these side effects were so bad, the medical world stopped using it for humans in the United States by 1965.

Transition to Veterinary Medicine and Illicit Use: Late 1960s

After humans stopped using it, the drug found a new home in veterinary clinics. It was used as a tranquilizer for animals. But that didn’t stay clean for long. By the late 1960s, the drug started appearing on the streets. People were drawn to the way it changed their perception of reality. By 1969, the government stepped in and made making, selling, or even holding the drug a serious crime.

Regulatory Tightening and Peak Notoriety: 1970–1978

article - illustration 1

The early 1970s were a messy time. Authorities fought to get the drug off the streets, but it was spreading. Initially, it was a Schedule III substance, but the government soon realized that wasn’t enough.

In 1978, the law got much tougher, and it was moved to Schedule II. That same year, all legal use in animal medicine stopped. Why? Because better, safer options—like ketamine—were now available. During this time, the media painted a dark picture of the drug, often calling it the most dangerous substance in America. As one researcher noted, the societal impact of PCP during this decade fundamentally changed how the public perceived chemical safety.

Decline and Modern Scientific Legacy

Following the heavy crackdown in the late 70s, use of the drug slowed down significantly. By 1990, the number of high school students reporting any use had dropped from 13% down to under 3%.

While you don’t hear about it as much on the street today, the drug is still vital in science. Its ability to create symptoms that look like schizophrenia has made it a key tool for researchers studying the brain. It helps scientists investigate the NMDA receptor and how it might trigger mental health disorders, which is a major focus in modern neurobiology.

References

DrugAbuse.com. (n.d.). PCP Facts, History, and Statistics. https://drugabuse.com/drugs/hallucinogens/pcp/history-statistics/

EBSCO. (n.d.). PCP | Health and Medicine | Research Starters. https://www.ebsco.com/research-starters/health-and-medicine/pcp

Healthline. (n.d.). PCP (Phencyclidine): 9 FAQs About Angel Dust. https://www.healthline.com/health/pcp

National Drug Intelligence Center. (n.d.). PCP Fast Facts. https://www.justice.gov/archive/ndic/pubs4/4440/index.htm

Petursson, H. (2018). DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). ACS Chemical Neuroscience. https://pubs.acs.org/doi/10.1021/acschemneuro.8b00266

PubMed. (2018). DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). https://pubmed.ncbi.nlm.nih.gov/29953199/

Wikipedia. (n.d.). Phencyclidine. https://en.wikipedia.org/wiki/Phencyclidine

Author

Dr. Thomas Walker, a seasoned Addiction Treatment Specialist and Psychiatrist, has dedicated his life to providing compassionate care to the Charleston community. Born and raised in Columbia, South Carolina, he developed a profound commitment to helping individuals struggling with addiction. 

Experienced medical professional in drug detox and rehab programs, focused on helping individuals overcome addiction and achieve lasting recovery. Expert in personalized addiction treatment plans and supportive care.

medical reviewer

MD, Board-Certified in Addiction Medicine

Medical Reviewer: Dr. Elena Ramirez is a board-certified addiction medicine specialist with over 15 years of clinical experience in substance use treatment and behavioral health. She earned her medical degree from the University of California, San Diego, and completed her residency in Psychiatry at Stanford University.

Sensitive male professional in a business suit, close-up portrait.

medical reviewer

MSW, Licensed Clinical Social Worker (LCSW)

Medical Reviewer: Marcus Bennett is a licensed clinical social worker specializing in addiction recovery and family systems therapy. He holds a Master of Social Work from the University of Michigan and has spent the past decade working in both inpatient and outpatient rehab settings.

Calm professional woman in white medical coat, healthcare worker, expert in drug detox and rehab treatments, focused on supporting addiction recovery and patient well-being.

medical reviewer

MD, Psychiatrist, Fellowship in Addiction Psychiatry

Medical Reviewer: Dr. Priya Desai is a board-certified psychiatrist with a subspecialty in addiction psychiatry. She completed her medical degree at Emory University and her fellowship at Columbia University Medical Center.

Professional man in suit for drug detox and rehab services.

medical reviewer

MPH, Certified Prevention Specialist (CPS)

Medical Reviewer: Jamal Thompson is a public health strategist focused on substance abuse prevention and community outreach. He holds a Master of Public Health from Johns Hopkins University and is a Certified Prevention Specialist through the IC&RC.

Related Articles